Featuring slide presentations and related
discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof
Peter Schmid, including the following topics:
Strategies to
Identify Patients with HER2-Low and HER2-Ultralow Breast
Cancer(0:00)
Case: A woman in
her mid 50s initially presenting with ER-positive, HER2 IHC 1+
locally advanced breast cancer who experiences progression to HER2
0 metastatic disease (20:53)
Case: A woman in
her early 60s with ER-positive, HER2 IHC 1+ metastatic breast
cancer (mBC) who experiences disease progression 8 months after
starting first-line CDK4/6 and aromatase inhibitor
(29:14)
Expanding the
Spectrum of Targeted Therapy (38:52)
Case: A woman in
her early 60s with HR-positive, HER2 IHC 1+ mBC who receives
fifth-line T-DXd resulting in stable disease (1:04:13)
Case: A woman in
her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an
ESR1 mutation who has ultralow HER2 expression on rebiopsy of new
liver lesions (1:12:35)
Identification
and Management of Adverse Events with T-DXd (1:20:27)
Case: A woman in
her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced
persistent low-grade nausea with T-DXd that resolved with
olanzapine (1:34:02)
Case: A woman in
her early 60s with ER-positive, HER2 2+ mBC who received T-DXd
resulting in fatigue and asymptomatic interstitial lung
disease (1:48:58)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.